Operating Income
Operating Income
Neurocrine Biosciences Operating Income decreased by 8.3% to $193.4M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 719.5%, from $23.6M to $193.4M. Over 3 years (FY 2022 to FY 2025), Operating Income shows an upward trend with a 35.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionOperating Income
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase signals improved profitability and operational efficiency, while a decrease indicates rising costs or declining sales.
Detailed definition
Operating income is the profit realized from core business operations after deducting all operating expenses from total...
Peer comparison
Standard financial metric; peers are compared based on operating margin percentages.
Metric ID:
operating_incomeHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $62.8M | $44.5M | $3.1M | $54.7M | $87.8M | $103.4M | -$114.2M | $73.6M | $141.2M | $150.3M | $99.3M | $145.4M | $183.8M | $142M | $23.6M | $145.6M | $239M | $210.9M | $193.4M |
| QoQ Change | — | -29.1% | -93.0% | >999% | +60.5% | +17.8% | -210.4% | +164.4% | +91.8% | +6.4% | -33.9% | +46.4% | +26.4% | -22.7% | -83.4% | +516.9% | +64.1% | -11.8% | -8.3% |
| YoY Change | — | — | — | -12.9% | +97.3% | — | <-999% | +34.6% | +60.8% | +45.4% | +187.0% | +97.6% | +30.2% | -5.5% | -76.2% | +0.1% | +30.0% | +48.5% | +719.5% |
Range-$114.2M – $239M
CAGR+28.4%
Avg YoY Growth-168.5%
Median YoY Growth+34.6%
Current Streak2 quarters decline
Operating Income at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's operating income?
- Neurocrine Biosciences (NBIX) reported operating income of $193.4M in Q1 2026.
- How has Neurocrine Biosciences's operating income changed year-over-year?
- Neurocrine Biosciences's operating income increased by 719.5% year-over-year, from $23.6M to $193.4M.
- What is the long-term trend for Neurocrine Biosciences's operating income?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's operating income has grown at a 35.5% compound annual growth rate (CAGR), from $249M to $619.1M.
- What does operating income mean?
- Profit earned from core business activities before interest and taxes.